38 results about "Obesity associated disorder" patented technology

The present invention relates to a composition for treating obesity-related diseases comprising an insulinotropic peptide conjugate, more particularly, to a composition for treating obesity-related diseases comprising a conjugate prepared by covalently linking the insulinotropic peptide with a carrier substance via a non-peptidyl linker, and a method for treating obesity-related diseases by using the same. In particular, the composition for treating obesity-related diseases according to the present invention remarkably improves the efficacy of suppressing food intake and its duration to reduce body weight and body fat, thereby being useful for the treatment of obesity-related diseases.

The invention provides novel non-peptidic NPY Y2 receptor inhibitors useful in treating or preventing: anxiolytic disorders or depression; injured mammalian nerve tissue; conditions responsive to treatment through administration of a neurotrophic factor; neurological disorders; bone loss; substance related disorders; sleep / wake disorders; cardiovascular disease; obesity; or an obesity-related disorder. Compounds of the invention are also useful in modulating endocrine functions, particularly endocrine functions controlled by the pituitary and hypothalamic glands, and are therefore useful in the treatment or prevention of inovulation and infertility.

The invention provides for methods of treating obesity or an obesity-associated disorder.

The invention discloses a bacterial strain as well as a composition and application, and relates to the technical field of strain separation and application. The Cristinia sp. provided by the invention can be applied to treatment or prevention of liver function impairment and liver function impairment related diseases, alimentary canal mucosal injury and alimentary canal mucosal injury related diseases, diabetes, obesity and obesity related diseases. The inventor verifies that the Cristinia sp. provided by the invention has no toxic or side effect on the kidney and can reduce the weight of the liver; the initial steatohepatitis focus can be treated; fat accumulation of liver cells can be slowed down; AST and ALT in serum can be reduced; and abdominal white fat inflammatory lesion can be reduced. The Cristinia sp. can also repair the digestive tract mucosa, recover the barrier function of the mucosa, and prevent and treat intestinal leakage, peptic ulcer and other diseases caused by barrier function impairment. The Cristinia sp. also has the effects of reducing fasting blood-glucose of a body, regulating insulin level and reducing body fat of mammals, and has the effects of preventing and treating diabetes and improving the metabolic function of obese patients.

The present invention relates to pharmaceutical compositions comprising a combination of a particular dipeptidyl peptidase-IV (DPP-IV) inhibitor and a particular cannabinoid CB?1#191 receptor antagonist / inverse agonist, kits containing such combinations and methods of using such compositions for the treatment of diabetes, diabetes associated with obesity, diabetes-related disorders, obesity, and obesity-related disorders.

The invention provides a Leg1 protein and application thereof in obesity-related diseases, relating to the technical field of functions and application of genes. By using an mLeg1-gene knockout mouse as the research object, means of genetics, molecular biology, biochemistry and cytobiology are utilized to perform very comprehensive research on the functions of the mLeg1 gene. The research result indicates that the mLeg1 protein (SEQ ID NO.2) and homologous proteins thereof (SEQ ID NO.1 and SEQ ID NO.5-8) and coding genes thereof can be used as brand-new targets for synthesizing related drugs from fat, can be used in the fields of preparation of drugs for treating obesity or losing weight, preparation of drugs for treating fat deficiency or increasing weight, preparation or screening of drugs for treating diabetes and preparation of drugs for adjusting fat accumulation of vertebrates and other related drugs for adjusting fat synthesis, and provides a brand-new idea for developing and researching drugs for adjusting internal fat synthesis and accumulation of vertebrates or treating fat-related diseases.

The present invention relates to the use of a genetically modified non-human animal as an animal model for obesity or obesity-related disorders, wherein the amount of Lysine-specific Demethylase 1 (LSD1) in at least one tissue or at least one cell type of said animal is reduced.

The present invention relates to Bicyclic Pyranone Derivatives, their compositions and uses for treating or preventing a metabolic disorder, dyslipidemia, a cardiovascular disease, a neurological disorder, a hematological disease, cancer, inflammation, a respiratory disease, a gastroenterological disease, diabetes, a diabetic complication, obesity, an obesity-related disorder or non-alcoholic fatty liver disease. Formula (I). Y is —C— when an optional and additional bond is present and Y is —CH— when an optional and additional bond is not present; Z is —O—, —NH— or —N(alkyl)- when the optional and additional bond between Y and Z Is absent, and Z Is —N— when the optional and additional bond between Y and Z is present; R1 is H1 halo or —CN; R2 is alkyl, alkenyl or -(alkyleneVcydoalkyl; t is 0 or 1; R3 is O when the optional and additional bond between Y and R3 is present, and R3 is alkyl.haloalkyl.—C(0)0R5.-alkylene-O-alkyt or —O-alkyl when the optional and additional bond between Y and R3 is absent: R4 is H, alkyl or aryl, wherein an aryl group can be unsubstituted or optionally substituted.

The present invention is directed to new genetic variants or polymorphisms at the perilipin locus (PLIN) including PLIN1: 6209T (allele 1)>C (allele 2); PLIN3 10171 (allele 1) A>T (allele 2); PLIN4: 11482G (allele 1)>A (allele 2); PLIN5: 13041A (allele 1)>G (allele 2) and PLIN6: 14995A (allele 1)>T (allele 2), and their use in diagnostic and prognostic applications for obesity and obesity-related diseases, such as metabolic syndrome and cardiovascular disease.

The invention provides human-derived lactobacillus mucosae and application thereof, and particularly provides human-derived lactobacillus mucosae. The invention further provides a composition for treating and preventing obesity and related diseases thereof and a method for reducing weight and / or blood fat. Experiments show that the lactobacillus mucosae can reduce blood fat and atherosclerosis, and therefore can be applied to treatment and prevention of obesity and related diseases (such as cardiovascular diseases).

The present invention relates to obesity related diseases, such as cancer of non-alcoholic fatty liver disease (NAFLD). Tissue perfusion is currently investigated by using dynamic contrast-enhanced magnetic resonance imaging which is an invasive technique and does not provide enough accuracy. As a result, the inventors worked on post-processing images of subcutaneous adipose tissue or the epididymal adipose tissue taken with a magnetic resonance imaging technique and a multifrequency magnetic resonance elastography technique to obtain parameters such as loss modulus and storage modulus which are more accurate for a diagnosing purpose. This post-processing method may be applied for a method for predicting that a subject is at risk of suffering from said disease, identifying a therapeutic target or a biomarker and screening compounds useful as medicine.

The present invention is directed to immunmodulators in the form of compositions, compounds, proteins and / or fragments with RNase activity thereof for use in the treatment of diseases associated with fat accumulation, including obesity and obesity-related disorders and metabolic disorders.

The present invention relates to a controlled release formulation comprising the active compounds tesofensine and a beta blocker, such as metoprolol or carvedilol, or a pharmaceutically acceptable salt thereof. The invention further relates to use of the controlled release formulation in a method of treatment of diabetes, obesity or an obesity associated disorder.

The invention discloses a combined medicine containing microorganisms and a hypoglycemic and lipid-lowering medicine, and relates to the technical field of strain separation and application. The combined medicine containing the microorganisms and the blood glucose and lipid lowering medicine can be applied to treatment or prevention of liver function impairment, liver function impairment related diseases, diabetes mellitus, obesity and obesity related diseases. The inventor verifies that the combined medicine containing the microorganisms and the hypoglycemic and lipid-lowering medicine has the technical effect of synergistic interaction, the combined medicine has the treatment effect better than that of the single application of the microorganisms or the single application of the hypoglycemic and lipid-lowering medicine, and the microorganisms can enhance the weight losing effect of the hypoglycemic and lipid-lowering medicine, improve abnormal glucose tolerance and reduce fasting blood glucose. In addition, the combined medicine has no toxic or side effect on the kidney and can reduce the weight of the liver.

The present invention relates to the field of metabolic research, in particular the discovery of compounds effective for reducing body mass and useful for treating obesity-related diseases and disorders. The obesity-related diseases or disorders envisioned to be treated by the methods of the invention include, but are not limited to, hyperlipidemia, atherosclerosis, insulin resistance, diabetes, and hypertension. In particular, the invention provides for methods of identifying and using AGONISTS and ANTAGONISTS of XOBESIN activity, wherein said activity is selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity.

The present invention provides methods for determining a putative agent that treats or prevent obesity and / or obesity related diseases comprising contacting cells with the putative agent and measuring the activity and / or level of Maf1 and / or the activity and / or level of KIAA1875. The present invention also provides the agent identified by the methods herein and methods of treating or preventing obesity and / or obesity related diseases in a subject comprising administering to the subject a therapeutically effective amount of an agent that inhibits or downregulates Maf1 and / or activates or upregulates KIAA1875.

The present invention discloses Growth Factor HTTER36 (GDF3) polypeptides and polynucleotides encoding such polypeptides. Also provided is a procedure for producing such polypeptides by recombinant techniques and therapeutic uses of the polypeptides which include the diagnosis, prevention, and treatment of wasting disorders. Also disclosed are antagonists against such polypeptide and their therapeutic uses which include the diagnosis, prevention, and treatment of obesity and obesity-related disorders. Also disclosed are diagnostic assays for detecting altered levels of the polypeptide of the present invention and mutations in the nucleic acid sequences which encode the polypeptides of the present invention.

Polypeptides and proteins that include a fragment of a ClpB protein and compositions therefrom. Methods of treatment and / or prevention of inflammation, in particular overweight and / or obesity-related diseases and disorders, with the polypeptides and proteins. Also, methods of inducing satiation, prolonging satiety, reducing meal size, reducing food intake, controlling weight gain and stimulating weight loss with the polypeptides and proteins.

The present invention relates to the use of a genetically modified non-human animal as an animal model for obesity or obesity-related disorders, wherein the amount of Lysine-specific Demethylase 1 (LSD1) in at least one tissue or at least one cell type of said animal is reduced.

Provided are gut microbes or cultures having anti-obesity efficacy and a pharmaceutical composition containing them. The gut microbes or cultures have anti-obesity efficacy by lowering fatty acid concentration of the gut fluid contents in a mammalian gastrointestinal tract for the prevention and treatment of obesity and obesity related diseases. This invention demonstrated that said gut microbes having anti-obesity efficacy by lowering fatty acid concentration of the gut fluid contents in the gastrointestinal tract of mammals have the anti-obesity efficacy as much as that of the representative anti-obesity drug, orlistat, without any side effects in animal experiments and clinical trials. Therefore, the gut microbes h can be used to develop universal anti-obesity drugs for obese patients, contributing greatly to the health of mankind.

The invention discloses a protein clusterin-clusterin related to obesity-related diseases, and a coding gene CLU (Clusterin) of the protein. The invention further discloses application of the protein clusterin related to the obesity-related diseases and the coding gene of the protein clusterin in preparation of drugs for preventing and treating the obesity-related diseases or kits for detecting the obesity-related diseases. The invention provides a gene or protein cluster related to obesity, and provides a theoretical basis and a new drug target for research and development of obesity drugs.

This invention relates to novel octahydroquinolizines for treatment or prevention of diabetes mellitus and its complications, for treatment or prevention of hyperlipidemia, for treatment of diabetic dyslipidemia, for treatment or prevention of the metabolic syndrome, for treatment of diseases related to metabolic dysfunction, for treatment of obesity or obesity-related diseases. The invention also includes pharmaceutical compositions and kits comprising these compounds alone or in combination with other drugs or compounds aiming towards an improved treatment or prevention of the aforementioned diseases or syndromes in humans or animals.

The research is different from other previous researches, and the action mechanism of the AdipoRon for treating the type 2 diabetes mellitus is discussed by applying a biological method. Liver cells are taken as experimental subjects, an experimental group for blocking a P13 / Akt signal channel is constructed, then AdipoRon is given, expression of saccharide genes related to the liver cells is analyzed, and the cellular mechanism of the AdipoRon for treating type 2 diabetes mellitus is discussed. At present, the research is not reported at home and abroad. The current method for treating the type 2 diabetes mellitus almost needs reasonable diet and exercise, and generates adverse effects such as hypoglycemia and weight gain, and the excessive caloric intake can be safely reduced by orally taking the AdipoRon, and the consequence caused by the lifestyle of sedentariness can be relieved, so that the AdipoRon provides a novel treatment method. By using the method, lots of expenditures for purchasing db / db mice and double-gene knockout mice can be saved.

Provided are uses of human Nectin-2 protein. Nectin-2 protein, derived protein thereof or modified protein thereof can effectively inhibit obesity and diabetes, and are also used to treat obesity-related diseases including hypertension, and hyperlipemia, etc. The Nectin-2 protein not only reduces blood glucose, but also improves the body glucose metabolism, and enhances sensitivity to tissue insulin by improving energy metabolism of the body, and improves adaptability to cold stimulation by activating fatty acid metabolism of the body.

Provided is an application of Butyribacter intestini in the treatment and prevention of obesity and obesity-related diseases. Also provided is a composition for the treatment and prevention of obesity and obesity-related diseases.